RecruitingPhase 2NCT07394153
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
- Principal Investigator
- Francisca Ferrer Marín, M.D.; Ph.D., M.DFundación Jimenez Díaz
- Intervention
- Pacritinib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (13)
- Hospital del Mar Barcelona, Barcelona, Barcelona, Spain
- Hospital Universitario Vall d´Hebron, Barcelona, Barcelona, Spain
- Hospital Clinic de Barcelona, Barcelona, Barcelona, Spain
- Hospital Universitario de Jerez, Jerez de la Frontera, Cádiz, Spain
- Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Spain
- Hospital Universitario Ramon y Cajal, Madrid, Madrid, Spain
- Fundación Jimenez Díaz, Madrid, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
- Hospital General Universitario Morales Meseguer, Murcia, Murcia, Spain
- Hospital Universitario de Salamanca, Salamanca, Salamanca, Spain
- Hospital Clínico Universitario Valencia, Valencia, Valencia, Spain
- Hospital General Universitario de Valencia, Valencia, Valencia, Spain
- Hospital Universitario Doctor Peset, Valencia, Valencia, Spain
Collaborators
Swedish Orphan Biovitrum · MFAR Clinical Research S.L.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07394153 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07590986Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative NeoplasmUniversité Catholique de Louvain
- RECRUITINGPHASE1NCT07480824To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University